CTT制药向SEC提交报告，资金提升至1000万美元，推动药物递送技术进步。 CTT Pharmaceutical files for SEC reporting, boosts funding to $10M, advances drug delivery tech.

CTT药品控股公司(OCCQB:CTTH)向证交会提交了S-1号表格,逐步成为一家全面报告的公司。 CTT Pharmaceutical Holdings (OTCQB:CTTH) has filed a Form S-1 with the SEC, advancing its path to becoming a fully reporting company. 该公司正在将其股票信贷额度从300万美元扩大到1 000万美元,与RH2平等伙伴合作,为产品开发和商业化提供资金。 The company is expanding its equity line of credit from $3 million to $10 million with RH2 Equity Partners to fund product development and commercialization. 它获准在其小鼠增长薄薄膜口服交付技术上发表一份经同行审查的手稿,并计划于2026年编写更多的研究论文。 It received approval to publish a peer-reviewed manuscript on its micelle-enhanced thin film oral delivery technology, with additional research papers planned for 2026. CTT在其专利提供平台的制造准备和监管调整方面也正在取得进展,该平台旨在改进药物吸收和患者方便度,改善整个制药和营养市场。 CTT is also making progress toward manufacturing readiness and regulatory alignment for its patented delivery platform, which aims to improve drug absorption and patient convenience across pharmaceutical and nutraceutical markets.